2020: The Investor Year of Action on Antibiotics?
Vibeka Mair of the Responsible Investor writes about a new collaboration involving the Access to Medicine Foundation to galvanise investor efforts to address AMR.
At launch of the new Antimicrobial Resistance Benchmark during a high-level panel discussion at the 2020 WEF Annual Meeting, a new collaboration between the UK Government, the Access to Medicine Foundation, the FAIRR Initiative and the Principles for Responsible Investment was announced.
The article shines light on the aim of the initiative which is to encourage and guide investors to use an “AMR lens” when making decisions and engaging with companies.
In the article Alice Evans, Co-Head of the Responsible Investment team at BMO Global Asset Management, is quoted saying that "the Access to Medicine Foundation’s AMR Benchmark is a useful tool to analyse pharmaceutical companies’ strategies to combat AMR."